Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.05 USD
Change Today -0.25 / -3.01%
Volume 4.1K
HSGX On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

histogenics corp (HSGX) Snapshot

Open
$8.37
Previous Close
$8.30
Day High
$8.37
Day Low
$8.05
52 Week High
12/3/14 - $12.97
52 Week Low
01/28/15 - $7.04
Market Cap
106.4M
Average Volume 10 Days
9.1K
EPS TTM
--
Shares Outstanding
13.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HISTOGENICS CORP (HSGX)

Related News

No related news articles were found.

histogenics corp (HSGX) Related Businessweek News

No Related Businessweek News Found

histogenics corp (HSGX) Details

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace. Its product candidate includes NeoCart, which is in Phase III clinical trials, a first-line therapy for full thickness knee chondral lesions in skeletally mature adults age 18 to 55. The company has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

42 Employees
Last Reported Date: 03/27/15
Founded in 2000

histogenics corp (HSGX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $224.3K
Senior Vice President of Manufacturing, Opera...
Total Annual Compensation: $309.2K
Chief Medical Officer
Total Annual Compensation: $274.3K
Compensation as of Fiscal Year 2014.

histogenics corp (HSGX) Key Developments

Histogenics Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:40 AM

Histogenics Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Adam D. Gridley, Chief Executive Officer, President and Director.

Histogenics Corporation Appoints Stephen J. Dipalma as Interim Chief Financial Officer, Effective March 31, 2015

The Board of Directors of Histogenics Corporation has appointed Stephen J. DiPalma, Managing Director of Danforth, as interim Chief Financial Officer, effective March 31, 2015 upon the resignation of Kevin McArdle, the Company's Chief Financial Officer. Mr. DiPalma, age 56, is Managing Director for Danforth Advisors LLC, and brings more than 25 years of experience in life sciences and healthcare, including founding two start-ups, working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies, and his work as a consultant with Danforth Advisors, LLC clients.

Histogenics Corporation Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 03:30 PM

Histogenics Corporation Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 03:30 PM. Venue: MGM Grand Hotel, Las Vegas, Nevada, United States. Speakers: Adam D. Gridley, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSGX:US $8.05 USD -0.25

HSGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HSGX.
View Industry Companies
 

Industry Analysis

HSGX

Industry Average

Valuation HSGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HISTOGENICS CORP, please visit www.histogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.